Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.
Authors of this article are:
Seront E, Catala G, Dermine A, Lejeune S, Rysselinck S.
A summary of the article is shown below:
Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In the first-line setting, platinum-based chemotherapy is the standard of care but resistance rapidly occurs. After failure of platinum-based therapy and in cisplatin-ineligible patients, therapeutic options are limited. Malignant cells evolve mechanisms to evade immune recognition, including the expression of cell-surface molecules, named immune checkpoints, on tumor and tumor-specific lymphocytes. Immunotherapy, by targeting these checkpoints, represents a new tool to improve the patient outcome in advanced urothelial carcinoma (UC). Recently, the US FDA approved, in a short time, several immune checkpoint inhibitors in metastatic UC, both after failure of platinum-based therapy and in first-line setting in cisplatin-ineligible patients. This article aims to review the place of immunotherapy in advanced UC.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
atezolizumab;avelumab;durvalumab;gene signature;immune checkpoint inhibitors;immunotherapy;nivolumab;pembrolizumab;programmed death ligand-1 (PD-L1);urothelial carcinoma
Categories: Science News